RAG-01 in Non-Muscle Invasive Bladder Neoplasms: NCT07777848 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
114
Planned enrollment
2029-03-01
Primary-completion proxy
Executive view
NCT07777848 evaluates RAG-01 in Non-Muscle Invasive Bladder Neoplasms. The disclosed sponsor is Ractigen Therapeutics, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC), assessed over 24 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07777848 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Non-Muscle Invasive Bladder Neoplasms landscape. Drug & Asset MCP drug_fetch was queried for RAG-01, while Company & Deal Intelligence MCP organization_fetch was queried for Ractigen Therapeutics.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07777848 | RAG-01 | Phase 2 / Not yet recruiting | Ractigen Therapeutics | China | Efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) 24 months | 2029-03-01 |
| NCT07808216 | Toripalimab | Phase 2 / Not yet recruiting | Tianjin First Center Hospital | Geography not reported | Pathologic Complete Response (CR) Rate at 3 Months 3 months after the first dose of study treatment. | 2028-10-01 |
| NCT07804056 | Alpha-lactalbumin-oleic acid(Azanta A/S) | Phase 3 / Not yet recruiting | Hamlet BioPharma AB | Czechia | Event-Free Survival (EFS) From randomization until the occurrence of an EFS event or study comp… | 2029-07-01 |
| NCT07783815 | Disitamab Vedotin | Phase 1 / Not yet recruiting | Xiangya Hospital Central South University | China | The one-year recurrence-free survival rate of patients with high-risk NMIBC One year after the treatment | 2027-09-01 |
| NCT07747740 | Gemcitabine Hydrochloride | Phase 2 / Recruiting | N N Blokhin Russian Cancer Research Center | Russia | 12-Month Event-Free Survival 12 months after randomization | 2029-12-30 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07777848 is a Phase 2, not yet recruiting study with 114 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC)” over “24 months.” The retrieved endpoint description is: Event-Free Survival rate.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 114 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Non-Muscle Invasive Bladder Neoplasms. These records do not establish direct evidence for NCT07777848 unless the registration number matches.
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Not Applicable; n=4; No numerical result field reported Source: https://clinicaltrials.gov/ct2/show/results/NCT02657486
UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
Phase 3; n=240; Adverse Event: dysuria = Treatment-emergent adverse events that occurred in ≥10% of enrolled patients (N = 240) was dysuria Source: https://pubmed.ncbi.nlm.nih.gov/41880645/
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Inva…
Phase 2; n=220; Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate = 46.4 percentage of participants (95% Confidence Interval, 27.5 - 66.1); Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate = 82.4 percentage of participants (95% Confidence Interval, 72.6 - 89.8) Source: https://clinicaltrials.gov/ct2/show/results/NCT04640623
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “RAG-01.” The report therefore avoids inferring modality, target or global development stage from the name alone.
Ractigen Therapeutics is indexed in China with the website http://www.ractigen.com. Engages in research and development of innovative drugs and disease treatment methods The record lists 19 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether RAG-01 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07777848
Protocol source: https://clinicaltrials.gov/study/NCT07777848
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
RAG-01 in Non-Muscle Invasive Bladder Neoplasms is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) and 2029-03-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
